Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells
about
Novel immunotherapies for hematologic malignanciesBispecific T-cell engagers for cancer immunotherapy.Theranostic impact of NG2/CSPG4 proteoglycan in cancerDiagnostic and prognostic biomarkers in melanoma.CSPG4: a prototype oncoantigen for translational immunotherapy studies.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumorsBispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.Therapeutic potential and challenges of natural killer cells in treatment of solid tumorsChondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.Bispecific antibodies in cancer immunotherapyThe swinging pendulum of cancer immunotherapy personalization
P2860
Q27004436-490824A2-D3DF-4BA4-91B5-8F493EF19825Q27693313-290429AB-EF0E-41D1-92C4-588D54E853FCQ28085331-D46FB419-98B5-4883-8573-0F997A3535C4Q33862470-CC028526-927F-425B-9D17-87B47B5539CFQ33862585-F7257121-2700-4548-A71B-3C4B49167A2BQ34000700-BDE7B9B1-4CE9-4675-B0D8-2F067A6EDE56Q35808466-045A25BF-4898-431F-95A9-22D4DEDA7A61Q37078941-E4E07F97-43C3-421D-851C-434E43202B68Q37376659-9DC3CB5D-8C3E-45B1-BB6F-C29D37D2F873Q38478878-437FF4EB-1C7A-4555-8659-A72CF6866AE5Q38550541-EDE2C0D9-D4D7-4410-8929-CD591FB67E93Q38823747-292B6B0B-2CAD-4589-A122-B6E128F187BCQ41590699-5318BCB6-BB51-4DAF-886B-47B5488BC431Q41708676-BD041828-DB6C-473E-AC7C-BE427ED720AAQ47335259-F9493780-BE42-40B3-8458-B0A879951634Q47555734-6FAA1F3E-1830-4F24-A49B-BE1D89DFBF27Q47570404-50A47934-0E1A-4C89-8021-650D583F1942Q49805666-53B5EE5C-EAF6-4144-B77A-189A318E8AD5Q56893015-1DB0FF91-D280-4F86-9CD3-0ECABE6E49D2Q58924840-14133EFA-80DD-411F-8F8E-6D1198DE70DD
P2860
Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Redirected lysis of human mela ...... ngages patient-derived T cells
@ast
Redirected lysis of human mela ...... ngages patient-derived T cells
@en
type
label
Redirected lysis of human mela ...... ngages patient-derived T cells
@ast
Redirected lysis of human mela ...... ngages patient-derived T cells
@en
prefLabel
Redirected lysis of human mela ...... ngages patient-derived T cells
@ast
Redirected lysis of human mela ...... ngages patient-derived T cells
@en
P2093
P2860
P1476
Redirected lysis of human mela ...... ngages patient-derived T cells
@en
P2093
Donald L Morton
Hans F Schoellhammer
Hitoe Torisu-Itakura
Myung-Shin Sim
Patrick A Baeuerle
Reiko F Irie
Susanne Hausmann
Tobias Raum
P2860
P304
P356
10.1097/CJI.0B013E3182307FD8
P577
2011-10-01T00:00:00Z